Why the study?
Do NOACs improve safety and efficacy compared to VKAs in real-world obese patients with atrial fibrillation?
Do NOACs improve safety and efficacy compared to VKAs in real-world obese patients with atrial fibrillation?
In real-world obese patients with atrial fibrillation, NOACs demonstrate a favorable net clinical benefit and lower major bleeding risk compared to VKAs.
Answers are grounded in this paper and cite their sources.
Observational data suggest lower major bleeding with NOACs in obese AF; leaves open need for randomized confirmation.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Russo et al. (2020) studied Atrial Fibrillation. Nonvitamin K Antagonist Oral Anticoagulants was evaluated.
Synapse has enriched 10 related papers. Consider them for comparative context: